Send to

Choose Destination
Lancet Respir Med. 2019 Mar;7(3):195-197. doi: 10.1016/S2213-2600(19)30036-0.

Towards optimal treatment for latent Mycobacterium tuberculosis infection.

Author information

University College London Institute for Global Health, University College London, London, UK.
Union Headquarters, International Union Against Tuberculosis and Lung Disease, Paris, France; Department of Medicine, Kenyatta University, Nairobi, Kenya.
Champalimaud Foundation, Centre for the Unknown, Avenida Brasília, Lisbon, Portugal.
Division of Infection and Immunity, Center for Clinical Microbiology, University College London, London, UK; National Institute of Health Research Biomedical Research Centre, University College London Hospitals, London NW1 2PG, UK. Electronic address:

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center